New York - Researchers have identified a molecular biomarker that was shown in a study to predict survival in melanoma patients, independently of tumor thickness and other known prognostic indicators.
Iovance Completes Biologics License Application (BLA) Submission for Advanced Melanoma Drug
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
5 Perspectives on Laser Treatment in Dermatology
The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice
Adel Haque, MD, Provides His Best Advice for New Dermatologists
Recent Povorcitinib 2b Study Shows Improved Repigmentation